$482 Million is the total value of TANG CAPITAL MANAGEMENT LLC's 20 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 37.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HRTX | HERON THERAPEUTICS INC | $84,527,000 | -31.1% | 7,907,087 | 0.0% | 17.55% | -28.2% | |
| RCKT | ROCKET PHARMACEUTICALS INC | $75,676,000 | -32.5% | 2,531,800 | 0.0% | 15.71% | -29.6% | |
| ANAB | ANAPTYSBIO INC | $71,290,000 | +4.6% | 2,628,678 | 0.0% | 14.80% | +9.1% | |
| ODT | ODONATE THERAPEUTICS INC | $45,147,000 | -16.6% | 15,514,566 | 0.0% | 9.37% | -13.0% | |
| LJPC | LA JOLLA PHARMACEUTICAL CO | $40,096,000 | -6.8% | 10,049,224 | 0.0% | 8.32% | -2.8% | |
| APVO | APTEVO THERAPEUTICS INC | $27,174,000 | -31.2% | 1,760,000 | 0.0% | 5.64% | -28.2% | |
| ITOS | Buy | ITEOS THERAPEUTICS INC | $24,300,000 | +331.8% | 900,000 | +310.2% | 5.04% | +350.4% |
| CRVS | New | CORVUS PHARMACEUTICALS INC | $18,147,000 | – | 3,749,379 | +100.0% | 3.77% | – |
| ALT | Buy | ALTIMMUNE INC | $18,096,000 | +134.5% | 1,600,000 | +104.2% | 3.76% | +144.6% |
| VINC | VINCERX PHARMA INC | $16,665,000 | +24.5% | 1,030,634 | 0.0% | 3.46% | +29.8% | |
| CHRS | COHERUS BIOSCIENCES INC | $10,446,000 | +16.2% | 650,000 | 0.0% | 2.17% | +21.2% | |
| LIFE | New | ATYR PHARMA INC | $10,110,000 | – | 1,113,453 | +100.0% | 2.10% | – |
| LPTX | New | LEAP THERAPEUTICS INC | $10,025,000 | – | 2,500,000 | +100.0% | 2.08% | – |
| CCXI | CHEMOCENTRYX INC | $8,550,000 | +27.7% | 500,000 | 0.0% | 1.78% | +33.2% | |
| New | TANGO THERAPEUTICS INC | $6,061,000 | – | 468,750 | +100.0% | 1.26% | – | |
| RVPH | REVIVA PHARMACEUTCLS HLDGS I | $4,884,000 | -16.3% | 1,200,000 | 0.0% | 1.01% | -12.7% | |
| EQ | EQUILLIUM INC | $4,092,000 | +15.8% | 600,000 | 0.0% | 0.85% | +20.9% | |
| RLMD | RELMADA THERAPEUTICS INC | $2,621,000 | -18.1% | 100,000 | 0.0% | 0.54% | -14.6% | |
| NXTC | NEXTCURE INC | $2,022,000 | -16.1% | 300,000 | 0.0% | 0.42% | -12.5% | |
| ASLN | New | ASLAN PHARMACEUTICALS LTDads | $1,736,000 | – | 975,305 | +100.0% | 0.36% | – |
| BCTG | Exit | BCTG ACQUISITION CORP | $0 | – | -468,750 | -100.0% | -1.06% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HERON THERAPEUTICS INC | 37 | Q3 2023 | 55.0% |
| LA JOLLA PHARMACEUTICAL CO | 34 | Q2 2022 | 37.1% |
| ROCKET PHARMACEUTICALS INC | 20 | Q3 2023 | 31.6% |
| BIOMARIN PHARMACEUTICAL INC | 18 | Q3 2017 | 12.1% |
| ODONATE THERAPEUTICS INC | 17 | Q4 2021 | 69.8% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 18.4% |
| COHERUS BIOSCIENCES INC | 15 | Q3 2023 | 2.7% |
| EQUILLIUM INC | 13 | Q3 2023 | 1.2% |
| RELMADA THERAPEUTICS INC | 12 | Q4 2022 | 6.2% |
| MIRATI THERAPEUTICS INC | 11 | Q3 2023 | 10.9% |
View TANG CAPITAL MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 4 | 2024-02-02 |
| 4 | 2023-12-18 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-10-13 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-06-01 |
| 4 | 2023-06-01 |
| 4 | 2023-05-30 |
View TANG CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.